Pioneering Microbiome Research with the Million Microbiome of Humans Project

May 9, 2023

Feature 1

Pioneering Microbiome Research with the Million Microbiome of Humans Project
Pioneering Microbiome Research with the Million Microbiome of Humans Project

MGI: Pioneering Microbiome Research with the Million Microbiome of Humans Project

MGI Tech Co. Ltd. (MGI), a global leader in life science technology, is making significant strides in the field of microbiome research. The company is at the forefront of the Million Microbiome of Humans Project (MMHP), a collaborative effort involving 21 institutes across over 10 nations throughout Europe. The project, launched in 2019, aims to sequence and analyze microbial DNA from a million human samples to construct a comprehensive microbiome map of the human body. This ambitious endeavor is set to create the world's largest human microbiome database, leveraging MGI's proprietary DNBSEQ™ technology.

The Importance of Microbiome in Human Health

The human microbiome plays a crucial role in our health and wellbeing. "Countless studies have highlighted the importance of the microbiome in human health and disease. Yet, our knowledge of the composition of the microbiome in different parts of the body across countries, ages, sexes, and in relation to human health and disease remains limited," said Duncan Yu, President of MGI. The MMHP aims to fill this knowledge gap, pushing forward microbial metagenomic research and empowering researchers within the microbiology community with access to MGI's innovative sequencing technology.

The Rise of Microbial Metagenomic Sequencing

Since the first description of the human microbiome was published in 2010, the field of human microbiome has rapidly expanded. Advances in genome sequencing have enabled researchers to better characterize the composition of the microbiome through identification of unculturable microbes. Metagenomics, coupled with high-throughput sequencing technologies, have revolutionized microbial ecology. Today, metagenomic sequencing has become both a powerful and popular tool for identifying and classifying complex microbial communities.

MGI's Role in Advancing Microbial Metagenomic Sequencing

MGI's innovative lab systems play a pivotal role in the MMHP Consortium, guaranteeing high-throughput processes, extreme precision, and high-quality data output. The dedicated, one-stop workflow begins with sample transfer on MGISTP-7000* high-throughput automated sample transfer processing system. It then goes through nucleic acid extraction and library preparation on MGISP-960 high-throughput automated sample preparation system. Lastly, DNBSEQ-T7* ultra-high throughput sequencer and DNBSEQ-G400* versatile benchtop sequencer enables an efficient, productive, and streamlined sequencing experience.

The Future of Microbiomics and Precision Medicine

"Microbiomics will be part of precision medicine in the future, and data from the microbiome biobank that will result from MMHP will be leveraged for therapeutic R&D," said Professor Stanislav Dusko Ehrlich of University College London, UK. With 21 public and private institutions and 10+ countries currently involved in MMHP, the project is actively seeking more research groups to take part in this landmark international microbiological research partnership.


Joining Forces for the Future of Microbiome Research

As MMHP enters its second phase, MGI continues to play a crucial role in providing the program with state-of-the-art research platforms and technologies. The project now aims to sequence and analyze a final total of one million samples, welcoming further exchange and participation from relevant organizations to jointly promote research and applications of cutting-edge translational medicine in the field of microbiome.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

MGI-Tech

Million Microbiome

Humans Project

Microbiome Research

Precision Medicine

Share

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

Mar 4, 2024

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Nov 10, 2023

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Latvia MGI Tech SIA advances DNA methylation research with significant European funding, achieving groundbreaking progress in biotechnology and innovation.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Jul 10, 2023

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Explore MGI's latest achievement as its DNBSEQ-T20×2 gene sequencing platform wins the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This post highlights MGI's commitment to innovation in the life science industry, their groundbreaking T20 gene sequencer, and how their technology is reshaping healthcare outcomes and the genetic industry.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.